Nutra Pharma Corp. (OTCQB: NPHC) is introducing new healthcare solutions to the globe. Through ReceptoPharm, a subsidiary, Nutra Pharma is discovering, researching and developing biopharmaceutical products to prevent and/or treat multiple sclerosis (MS), HIV/AIDS, adrenomyeloneuropathy (ADM), herpes, rheumatoid arthritis and pain.
Drug Discovery & Development
Nutra Pharma is in the business of acquiring, licensing and commercializing pharmaceutical products and technologies, along with homeopathic and ethical drugs for managing pain and neurological disorders, autoimmune and infectious diseases and cancer.
The company has several pipeline products both in the market and under research and development. Within the over-the-counter pain management market, Nutra Pharma is already marketing:
- Nyloxin and Nyloxin Extra Strength, homeopathic drugs used to alleviate moderate to severe chronic pain; and
- Pet Pain-Away, a homeopathic, non-addictive, non-narcotic pain reliever aimed at treating moderate to severe chronic pain in companion animals.
Nutra Pharma also has more than a few novel therapies in various stages of development, including:
- Nyloxin Military Strength, a pain relieving drug intended for sale to the U.S. Military and Veteran’s Administration;
- RPI-MN, a drug designed to treat viral diseases, such as HIV/AIDS and herpes;
- RPI-78, which is geared toward managing pain and arthritis;
- RPI-70, another pain reliever;
- Equine Nyloxin, a topical therapy for horses; and
- RPI-78M, which is designed to treat neurological diseases and autoimmune diseases, including MS, ADM and rheumatoid arthritis.
Through RPI-78M, Nutra Pharma reached new heights this year. In September, the U.S. Food and Drug Administration granted RPI-78M “orphan drug status” for the treatment of multiple sclerosis in children – a major milestone for the company. Not only is juvenile MS an important disease area, but it is one that is not being addressed by other drugs currently on the market. This creates a significant market opportunity for Nutra Pharma, as does the designation of RPI-78M as an orphan drug. With that label, Nutra Pharma has a 7-year period of market exclusivity in the U.S. once the drug is approved, and, based on its pre-clinical and open-label studies, the company feels quite strongly that it has the ability to successfully pass through this approval process.
For more information on the company, visit www.NutraPharma.com
Let us hear your thoughts: Nutra Pharma Corp. Message Board
